UCB : COVID-19 appears to have had no impact on UCB’s performance
>H1 far better than expected (revenues up +6% vs cons. and EPS +11% vs cons.) - UCB has published a very good H1 2020, 6% above consensus forecasts for revenues and underlying EBITDA, 11% above forecasts for EPS. Revenues were up 9% at constant forex driven by the persistently strong momentum on the group’s core products with Vimpat (+16% of reported growth), Cimzia (+8%) and Keppra (+13%). The recently launched Briviact posted growth of 40% - main negative point of t...UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.